Clearside Biomedical regains Nasdaq minimum bid price compliance via reverse split

Clearside Biomedical, Inc.

Received Nasdaq Panel letter on Oct 6, 2025 confirming compliance with Minimum Bid Price Requirement.
Compliance achieved by maintaining closing bid at $1.00+ for 10 consecutive business days after reverse stock split.
Reverse stock split effective Sept 12, 2025 was approved by stockholders and implemented to cure non-compliance.
Non-compliance notice originally received Feb 7, 2025; delisting hearing held Sept 16, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.